Masha Fridkis‐Hareli

Alexion Pharmaceuticals (United States) — United States

Immunology and Microbiology · Life Sciences

24h-index2.0kcitations64works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Immunotherapy and Immune Responses(28), T-cell and B-cell Immunology(25), Immune Cell Function and Interaction(18), Monoclonal and Polyclonal Antibodies Research(13), Complement system in diseases(8)

Publications64 total

The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a novel targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer mouse models
Molecular Immunology·2018· 24 cited
Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria
Blood·2015· 34 cited
Peptide-Based Immunotherapeutics and Vaccines 2015
Journal of Immunology Research·2015Open Access
Immune Responses and Vaccine Development for Cytomegalovirus Infections
British Journal of Medicine and Medical Research·2014
Peptide-Based Immunotherapeutics and Vaccines
Journal of Immunology Research·2014· 67 citedOpen Access
Design of Peptide Immunotherapies for MHC Class-II-Associated Autoimmune Disorders
Clinical and Developmental Immunology·2013· 15 citedOpen Access
mediated diseases - pathway convertase inhibitor for treatment of human complement alternative Design and development of TT30, a novel C3d-targeted C3/C5
2013· 1 cited
The human complement receptor type 2 (CR2)/CR1 fusion protein TT32, a targeted inhibitor of the classical and alternative pathway C3 convertases, prevents arthritis in active immunization and passive transfer models and acts by CR2-dependent targeting of CR1 regulatory activity
Immunobiology·2012· 12 cited
The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment opsonization
Blood·2012· 119 citedOpen Access
Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway–mediated diseases
Blood·2011· 117 citedOpen Access
A mentoring program for women scientists meets a pressing need
Nature Biotechnology·2011· 15 cited
Bioinformatics-Based Predictions of Peptide Binding to Disease-Associated HLA Proteins Suggest Explanation for Shared Autoimmunity
Immunology and Immunogenetics Insights·2011
TT30, a Novel Human Complement Inhibitor in Development for Paroxysmal Nocturnal Hemoglobinuria and Other Hemolytic Disorders, Demonstrates Red Blood Cell Surface Targeting and Retention In a Model of Complement Alternative Pathway-Mediated Hemolysis
Blood·2010
C3-Mediated Extravascular Hemolysis In Paroxysmal Nocturnal Hemoglobinuria: An In Vitro Model to Dissect Complement C3 Activation Comparing the Effects of Complement Inhibitors Eculizumab, 3E7 and TT30 on C3 Fragment Processing and Hemolysis of PNH Erythrocytes
Blood·2010· 2 cited
The human complement receptor type 2/factor H fusion protein TT30, an alternative pathway specific complement inhibitor, prevents hemolysis of erythrocytes from patients with paroxysmal nocturnal hemoglobinuria by membrane-targeting of factor H activity
Molecular Immunology·2010
The GP120 Molecule of HIV-1 and its Interaction with T Cells
Current Medicinal Chemistry·2010· 63 cited
Corrigendum to “Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy” [Cytokine 41 (2008) 315–321]
Cytokine·2008
Cytokine profiles in pemphigus vulgaris patients treated with intravenous immunoglobulins as compared to conventional immunosuppressive therapy
Cytokine·2008· 42 cited
Immunogenetic mechanisms for the coexistence of organ-specific and systemic autoimmune diseases
Journal of Autoimmune Diseases·2008· 46 citedOpen Access
Are desmoglein autoantibodies essential for the immunopathogenesis of pemphigus vulgaris, or just ‘witnesses of disease'?
Experimental Dermatology·2006· 31 cited
page 1 of 4Next →

Frequent Co-authors

Amiela Globerson(12), Jack L. Strominger(10), Joel N. H. Stern(10), Loya Abel(9), Michael Sela(7), Dvora Teitelbaum(6), Lars Fugger(6), Ramit Mehr(5), V. Michael Holers(4), Ruth Arnon(4), Celia F. Brosnan(4), Laura Santambrogio(4), Ayala Sharp(4), Antonio M. Risitano(3), Christopher Horvath(3), Michael Storek(3), Derin B. Keskin(3), Alan S. Perelson(3), Joaquı́n Zúñiga(3), Viviana Romero(3)